Today’s interims from Vectura are solid, with profitability ahead of expectations and pipeline development in line. The expected newsflow from Vectura over the coming months is significant: Utibron® vs. Anoro® Phase III data is due later this year, to be followed by the expected US launch of Utibron® and FDA approval of VR315/Generic Advair® by 10th May 2017. With two major near-term US launches ahead, we retain our Buy recommendation.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Vectura Group - Solid interim results
- Published:
23 Nov 2016 -
Author:
Dr Jens Lindqvist -
Pages:
3
Today’s interims from Vectura are solid, with profitability ahead of expectations and pipeline development in line. The expected newsflow from Vectura over the coming months is significant: Utibron® vs. Anoro® Phase III data is due later this year, to be followed by the expected US launch of Utibron® and FDA approval of VR315/Generic Advair® by 10th May 2017. With two major near-term US launches ahead, we retain our Buy recommendation.